Chinese english Japanese Germany Korea
ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >Protein tyrosine kinase /JAK / STAT >JAK inhibitors >Fedratinib

Fedratinib

Fedratinib Structure
CAS No.
936091-26-8
Chemical Name:
Fedratinib
Synonyms
CS-57;TG-101348;SAR-302503;Fedratinib;Fedratinib D9;TG101348, >=98%;2H9]-Fedratinib;SAR302503/TG101348;TG101348/TG-101348;Fedratinib/TG101384
CBNumber:
CB12485002
Molecular Formula:
C27H36N6O3S
Molecular Weight:
524.68
MOL File:
936091-26-8.mol
Modify Date:
2024/5/28 11:26:52
Request For Quotation

Fedratinib Properties

Melting point 180-182°C
Boiling point 713.7±70.0 °C(Predicted)
Density 1.247
storage temp. Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
solubility DMSO (Slightly), Methanol (Slightly)
form Beige powder.
pka 11.95±0.50(Predicted)
color White to Off-White
CAS DataBase Reference 936091-26-8

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS07,GHS08
Signal word  Warning
Hazard statements  H302-H361d
Precautionary statements  P264-P270-P301+P312-P330-P501
HS Code  29350090
NFPA 704
0
2 0

Fedratinib Chemical Properties,Uses,Production

Characteristics

Class: non-receptor tyrosine kinase
Treatment: myeloproliferative diseases
Oral bioavailability = 18–37%
Elimination half-life = 2–3 days
Protein binding = 91–96%

Uses

A potent, highly selective and ATP-competitive JAK2 inhibitor with an IC50 of 3 nM for JAK2 and JAK2V617F.

Pharmacokinetics

Fedratinib pharmacokinetics are characterized by prolonged duration of action: effective half-life of 41 hours, terminal half-life of approximately 114 hours, and elimination half-life of 2–3 days, which makes it suitable for once-daily dosing. In contrast, ruxolitinib has a short terminal half-life of approximately 3 h, suggesting that twice-daily administration of ruxolitinib is more suitable than once-daily dosing. Following oral administration, fedratinib is mainly bio-oxidized by CYP3A4 to give two major circulating metabolites in the plasma: the pyrrolidone derivative 1 and the N-butyric acid 2.
Fedratinib

Fedratinib Preparation Products And Raw materials

Raw materials

Preparation Products

Fedratinib Suppliers

Global( 170)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
A.J Chemicals 91-9810153283 New Delhi, India 6124 58 Inquiry
Capot Chemical Co.,Ltd. 571-85586718 +8613336195806 China 29798 60 Inquiry
ATK CHEMICAL COMPANY LIMITED +undefined-21-51877795 China 32760 60 Inquiry
career henan chemical co +86-0371-86658258 +8613203830695 China 29898 58 Inquiry
BOC Sciences +1-631-485-4226 United States 19553 58 Inquiry
Chongqing Chemdad Co., Ltd +86-023-6139-8061 +86-86-13650506873 China 39916 58 Inquiry
CONIER CHEM AND PHARMA LIMITED +8618523575427 China 49391 58 Inquiry
TargetMol Chemicals Inc. +1-781-999-5354 +1-00000000000 United States 19892 58 Inquiry
Dideu Industries Group Limited +86-29-89586680 +86-15129568250 China 24722 58 Inquiry
Supplier Advantage
CLEARSYNTH LABS LTD. 58
A.J Chemicals 58
Capot Chemical Co.,Ltd. 60
ATK CHEMICAL COMPANY LIMITED 60
career henan chemical co 58
BOC Sciences 58
Chongqing Chemdad Co., Ltd 58
CONIER CHEM AND PHARMA LIMITED 58
TargetMol Chemicals Inc. 58
Dideu Industries Group Limited 58

Related articles

  • A JAK2 inhibitor: Fedratinib
  • Fedratinib is a JAK2 inhibitor approved for treating adult patients with intermediate-2 or high-risk primary or secondary myel....
  • Jan 19，2024

Fedratinib Spectrum

N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide(936091-26-8)1HNMR

936091-26-8(Fedratinib)Related Search:

TG 100713 N,N-DIMETHYLHYDROXYLAMINE HYDROCHLORIDE N,N'-Dimethyl-1,3-propanediamine N,N-Dimethylbenzylamine N,N-Dimethylbenzamide
N,N-Dimethylpropionamide 5-PYRIDIN-4-YL-1H-INDAZOLE 3,3'-(2,4-Diamino-6,7-pteridinediyl)bisphenol TG6-10-1 N-(tert-Butyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide
AZD 1480 TG101209 MK-2206 2HCl Momelotinib LY 294002 HYDROCHLORIDE
Ruxolitinib
chevron_left

1of4

chevron_right
N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide TG-101348 N-TERT-BUTYL-3-(5-METHYL-2-(4-(2-(PYRROLIDIN-1-YL)ETHOXY)PHENYLAMINO)PYRIMIDIN-4-YLAMINO)BENZENESULFONAMIDE SAR-302503 BenzenesulfonaMide, N-(1,1-diMethylethyl)-3-[[5-Methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]aMino]-4-pyriMidinyl]aMino]- TG101348 (SAR302503) TG101348/TG-101348 SAR302503/TG101348 Fedratinib (SAR302503, TG101348) N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide TG 101348 Fedratinib (TG101348) Fedratinib TG101348, >=98% Fedratinib/TG101384 FEDRATINIB (SAR302503, TG101348);TG101348;TG 101348 N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl TG101348; TG 101348; TG-101348; SAR302503; SAR-302503; SAR 302503; FEDRATINIB. TG101348(Fedratinib) CS-57 TG-101348; TG 101348;SAR-302503;SAR 302503;SAR302503 TG 101348 - Fedratinib | SAR 302503 Fedratinib (SAR302503, TG101348), ≥98% Fedratinib (SAR302503) Fedratinib(TG101348,SAR302503) FEDRATINIB;SAR 302503;TG-101348;TG 101348 N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide USP/EP/BP N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzene-1-sulfonamide n-(1,1-dimethylethyl)-3-((5-methyl-2-((4-(2-(1-pyrrolidinyl)... Fedratinib D9 2H9]-Fedratinib TG101348 Fedratinib SAR302503 TG-101348 Apoptosis,SAR-302503,STAT5,Inhibitor,Janus kinase,phosphorylation,FLT3,myeloproliferative,JAK2V617F,orally,SAR302503,inhibit,Fedratinib,anti-proliferation,JAK2,TG 101348,TG101348,JAK,RET,anti-cancer Bazedoxifene Impurity 13 936091-26-8 C27H36N6O3S Inhibitor Inhibitors JAK STAT